Vaccines based on the native HIV Tat protein and on the combination of Tat and the structural HIV protein variant DeltaV2 Env

Microbes Infect. 2005 Nov;7(14):1392-9. doi: 10.1016/j.micinf.2005.07.016. Epub 2005 Sep 15.

Abstract

The promising results obtained with the HIV-1 Tat-based vaccines in mice, monkeys and humans, a better understanding of Tat immunomodulatory functions, as well as evidence that vaccination with trimeric V2 loop-deleted HIV-1 Env induces cross-clade neutralizing antibodies led to the rational design of a novel vaccine based on the combination of Tat and V2-deleted Env.

MeSH terms

  • AIDS Vaccines / adverse effects
  • AIDS Vaccines / genetics
  • AIDS Vaccines / immunology*
  • Adjuvants, Immunologic
  • Animals
  • Clinical Trials, Phase I as Topic
  • Gene Products, env / genetics
  • Gene Products, env / immunology*
  • Gene Products, tat / genetics
  • Gene Products, tat / immunology*
  • HIV Antibodies / blood
  • HIV-1 / immunology*
  • Humans
  • Macaca fascicularis
  • Male
  • Mice
  • Models, Animal
  • Neutralization Tests
  • Vaccines, Combined / adverse effects
  • Vaccines, Combined / genetics
  • Vaccines, Combined / immunology
  • Vaccines, Subunit / adverse effects
  • Vaccines, Subunit / genetics
  • Vaccines, Subunit / immunology
  • Vaccines, Synthetic / adverse effects
  • Vaccines, Synthetic / genetics
  • Vaccines, Synthetic / immunology
  • env Gene Products, Human Immunodeficiency Virus
  • tat Gene Products, Human Immunodeficiency Virus

Substances

  • AIDS Vaccines
  • Adjuvants, Immunologic
  • Gene Products, env
  • Gene Products, tat
  • HIV Antibodies
  • Vaccines, Combined
  • Vaccines, Subunit
  • Vaccines, Synthetic
  • env Gene Products, Human Immunodeficiency Virus
  • gp140 envelope protein, Human immunodeficiency virus 1
  • tat Gene Products, Human Immunodeficiency Virus